Phase I Study of Single-agent and Combined Checkpoint Inhibition After Allogeneic Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence

Trial Profile

Phase I Study of Single-agent and Combined Checkpoint Inhibition After Allogeneic Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Aug 2017 The protocol has been amended to include the efficacy endpoint of PFS as the secondary endpoint instead of the primary endpoint. The treatment table has also been amended with the changes in the weeks Nivolumab and Ipilimumab are administered.
    • 07 Aug 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2022.
    • 07 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top